z-logo
open-access-imgOpen Access
Rearrangement and amplification of c-abl sequences in the human chronic myelogenous leukemia cell line K-562.
Author(s) -
Steven Collins,
Mark Groudine
Publication year - 1983
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.80.15.4813
Subject(s) - chronic myelogenous leukemia , biology , microbiology and biotechnology , abl , chromosome 22 , gene , philadelphia chromosome , chromosomal translocation , immunoglobulin light chain , gene rearrangement , genetics , retrovirus , leukemia , antibody , signal transduction , tyrosine kinase
Structural rearrangements of specific cellular sequences (c-onc genes) homologous to acute transforming retrovirus oncogenes (v-onc genes) have been recently described in various malignancies. Here we show that human cellular sequences (c-abl) homologous to the transforming sequences of the mouse Abelson leukemia virus (v-abl) are amplified some 4- to 8-fold in K-562, a Philadelphia chromosome-positive cell line derived from a patient with chronic myelogenous leukemia in blast crisis. Restriction analysis of K-562 and other human DNA samples reveals a significant rearrangements of the c-abl sequences in this cell line. In addition, investigation of v-abl-related cytoplasmic RNA reveals relatively high levels of these sequences in K-562 compared to other normal and leukemia cells. We have also observed that lambda light chain constant region immunoglobulin genes are amplified in K-562, whereas kappa light chain sequences exhibit no amplification. These results are discussed within the context of the possibility that these Philadelphia chromosome-positive cells exhibit a reciprocal translocation involving chromosome 9 (containing c-abl) and chromosome 22 (containing the lambda light chain genes).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here